Neoadjuvant chemotherapy of capecitabine + epirubicin + cyclophosphamide combination therapy ( 'CEX' therapy) for HER-2 negative breast cancer, as retrospective study in our institute.

CONCLUSIONS: This study suggested that 'CEX' therapy as NAC could be an important option for individualized treatment. In particular, it was effective for TN breast cancer. PMID: 31776320 [PubMed - as supplied by publisher]
Source: Journal of Nippon Medical School - Category: Universities & Medical Training Authors: Tags: J Nippon Med Sch Source Type: research